ERBB2 and breast cancer: Around 20-30% of breast cancer cases are characterized with an overexpression of the human epidermal growth factor receptor 2 (HER2), and HER2-positive breast cancer is associated with increased aggressiveness in disease progression and worse clinical outcomes including lower disease-free survival and overall survival (OS) [3, 4].